Technical Review on Rite Aid and CVS Caremark: Flu and Generic Introductions
LONDON, January 23, 2013
LONDON, January 23, 2013 /PRNewswire/ --
With the worst flu season in years getting even more intense, companies in the
drug stores industry, including CVS Caremark Corporation (NYSE:CVS) and Rite
Aid Corporation (NYSE:RAD), are doing what they can to help combat what has
now become an epidemic. StockCall analysts have released their latest
technical research report on Rite Aid and CVS Caremark which can be downloaded
for free at http://www.stockcall.com/signup
Several companies have been working hard to keep up supplies of the vaccine,
with Rite Aid recently obtaining over 400,000 additional seasonal flu shots.
With more people receiving their shots daily, there is hope that the outbreak
will soon subside. Register today to access the free report on Rite Aid at
Elsewhere in the industry, companies have had their fair share of challenges
dealing with brand-name drug patent expirations and generic introductions.
Generics have had a negative effect on top-lines, and in some cases have also
crimped margins. Cost-cutting and streamlining initiatives have helped offset
some of the declines, and it will be interesting to see how individual
companies have performed as earnings season gets into full swing.
December results were mixed for industry players, as almost all companies were
negatively affected by generic introductions, while some also lost out due to
adverse weather. Rite Aid saw its December same store sales fall 2.2% when
compared to the same period last year, as generic introductions and lower
front-end sales more than offset a rise in flu-related shots and
CVS Caremark Corp. [ Free Report on CVS ] ^[ ^1 ^] , on the other hand, fared
better, posting a same store year-over-year December sales increase of 1.8%
from its CVS/pharmacy division. The company was ex-dividend yesterday, Tuesday
January 22 ^nd , and it is set to release its quarterly readings on February
06 ^th before the market opens.
1.CVS Caremark Corporation Technical Analysis [
StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at http://www.stockcall.com
Contact: William T. Knight, email@example.com, +1-646-396-9857 (9:00 am EST -
01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.